stockportfolio.pro
Relmada Therapeutics, Inc. (RLMD)
Healthcare · Biotechnology · NasdaqCM
Relmada Therapeutics, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2017 | 2018 | 2019 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | $-6.29M | $-8.96M | $-17.32M | $-15.01M | $-59.46M | $-125.75M | $-157.04M | $-98.79M | $-79.98M | $-57.39M |
| Net margin | — | — | — | — | — | — | — | — | — | — |
Source: Relmada Therapeutics, Inc. SEC filings (10-K). 16 years of history available in the interactive view.
Explore 16 years of Relmada Therapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track RLMD in your portfolio →
Relmada Therapeutics, Inc. financial history by metric
About Relmada Therapeutics, Inc.
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Relmada Therapeutics, Inc. — frequently asked questions
What is Relmada Therapeutics, Inc.'s revenue?
Relmada Therapeutics, Inc. (RLMD) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Relmada Therapeutics, Inc. profitable?
No — RLMD reported a net loss of $-57.39M in fiscal 2025.
What is RLMD's P/E ratio?
Relmada Therapeutics, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Relmada Therapeutics, Inc. have?
As of fiscal year 2025, RLMD carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Relmada Therapeutics, Inc.'s market cap?
Relmada Therapeutics, Inc. (RLMD) has a market capitalization of about $680.74M, based on the latest data in our nightly-refreshed cache.
When does Relmada Therapeutics, Inc.'s fiscal year end?
RLMD's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Relmada Therapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 16 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.